1. Home
  2. NCNO vs GENB Comparison

NCNO vs GENB Comparison

Compare NCNO & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nCino Inc.

NCNO

nCino Inc.

HOLD

Current Price

$17.10

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$13.75

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NCNO
GENB
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NCNO
GENB
Price
$17.10
$13.75
Analyst Decision
Buy
Strong Buy
Analyst Count
17
5
Target Price
$26.07
$25.00
AVG Volume (30 Days)
2.5M
479.1K
Earning Date
03-31-2026
05-03-2026
Dividend Yield
N/A
N/A
EPS Growth
115.15
N/A
EPS
0.05
N/A
Revenue
$594,781,000.00
N/A
Revenue This Year
$9.68
N/A
Revenue Next Year
$9.92
$45.45
P/E Ratio
$341.70
N/A
Revenue Growth
10.01
N/A
52 Week Low
$13.80
$11.00
52 Week High
$33.92
$14.21

Technical Indicators

Market Signals
Indicator
NCNO
GENB
Relative Strength Index (RSI) 58.28 58.88
Support Level $13.80 $11.21
Resistance Level $27.04 N/A
Average True Range (ATR) 0.94 1.10
MACD 0.34 0.14
Stochastic Oscillator 71.12 85.16

Price Performance

Historical Comparison
NCNO
GENB

About NCNO nCino Inc.

Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: